An international group of haematology scientists, including leading researchers in Oxford, have secured approval from the US Food and drug Administration (FDA) for a new leukaemia drug that has produced exciting results in clinical trials.
The development of Enasidenib has given hope to people with a form of acute myeloid leukaemia (AML), one of the most common and aggressive blood cancers in adults, which is incurable in most patients.
For the full story on Oxford Biomedical Research Centre website